CytomX Therapeutics, Inc. (CTMX)

Market Cap	720.10M
Revenue (ttm)	113.63M
Net Income (ttm)	28.02M
Shares Out	169.44M
EPS (ttm)	0.24
PE Ratio	17.74
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,608,824
Open	4.050
Previous Close	4.130
Day's Range	4.010 - 4.250
52-Week Range	0.400 - 4.620
Beta	2.37
Analysts	Strong Buy
Price Target	6.50 (+52.94%)
Earnings Date	Nov 6, 2025

About CTMX

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBO...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 8, 2015
• Employees: 121
• Stock Exchange: NASDAQ
• Ticker Symbol: CTMX
• Website: https://www.cytomx.com

Analyst Summary

According to 6 analysts, the average rating for CTMX stock is "Strong Buy." The 12-month stock price target is $6.5, which is an increase of 52.94% from the latest price.

Price Target

$6.5

(52.94% upside)

Analyst Consensus: Strong Buy